These results are consistent with mechanistic studies of adiponectin receptor agonists; for example, AdipoRon (another adiponectin receptor agonist) has been shown to enhance ceramidase activity and reduce Cer accumulation in diabetic cardiomyopathy, improving insulin resistance, reducing fibrosis and inflammation, and promoting cardiac function [27,32]. This evidence concerns the gene CBLN1 and Insulin resistance.